Patent application number | Description | Published |
20100160760 | DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS - Devices and methods for determining analyte levels are described. The devices and methods allow for the implantation of analyte-monitoring devices, such as glucose monitoring devices that result in the delivery of a dependable flow of blood to deliver sample to the implanted device. The devices include unique architectural arrangement in the sensor region that allows accurate data to be obtained over long periods of time. | 06-24-2010 |
20120179014 | DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS - Devices and methods for determining analyte levels are described. The devices and methods allow for the implantation of analyte-monitoring devices, such as glucose monitoring devices that result in the delivery of a dependable flow of blood to deliver sample to the implanted device. The devices include unique architectural arrangement in the sensor region that allows accurate data to be obtained over long periods of time. | 07-12-2012 |
20130310666 | DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS - Devices and methods for determining analyte levels are described. The devices and methods allow for the implantation of analyte-monitoring devices, such as glucose monitoring devices that result in the delivery of a dependable flow of blood to deliver sample to the implanted device. The devices include unique architectural arrangement in the sensor region that allows accurate data to be obtained over long periods of time. | 11-21-2013 |
20150087943 | DEVICE AND METHOD FOR DETERMINING ANALYTE LEVELS - Devices and methods for determining analyte levels are described. The devices and methods allow for the implantation of analyte-monitoring devices, such as glucose monitoring devices that result in the delivery of a dependable flow of blood to deliver sample to the implanted device. The devices include unique architectural arrangement in the sensor region that allows accurate data to be obtained over long periods of time. | 03-26-2015 |
Patent application number | Description | Published |
20080213333 | Methods and compositions for fostering and preserving bone growth - A method for augmenting bone in a subject in need thereof including installing within an interior portion of a bone located in the subject a sufficient amount of a biocompatible material to form a scaffold within the bone interior, wherein the scaffold serves as a support for the formation of new bone within the bone interior portion, and administering to the subject a sufficient amount of at least one bone augmentation agent to elevate blood concentration of at least one anabolic agent in the subject. The method may further include administering at least one anti-resorptive agent to the subject in an amount sufficient to substantially prevent resorption of new bone growth. In another embodiment, the method may further include a step of mechanically inducing an increase in osteoblast activity in the subject, wherein the elevation in blood concentration of the anabolic agent and the increase in osteoblast activity at least partially overlap in time. | 09-04-2008 |
20090023892 | Enzymatic reactions in the presence of keto acids - Conversion in vitro of X-Gly to X-alpha-hydroxy-Gly or X-NH | 01-22-2009 |
20120142586 | TREATMENT FOR OBESITY - The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like. | 06-07-2012 |
20120149635 | TREATMENT FOR OBESITY - The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like. | 06-14-2012 |
20120183582 | Oral Delivery of Peptides - Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing an active peptide that is amidated at a site that is not naturally amidated. | 07-19-2012 |
20120302497 | METHODS OF TREATING MEDICAL CONDITIONS USING CALCITONIN ANALOGS - The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like. | 11-29-2012 |
20120328666 | ORAL DELIVERY OF PEPTIDE PHARMACEUTICAL COMPOSITIONS - Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide. | 12-27-2012 |
20140249085 | CALCITONIN PRODUCTS AND THERAPIES FOR TREATING INFLAMMATORY OR DEGENERATIVE DISEASES - Calcitonin products and therapies for treating inflammatory or degenerative diseases are disclosed herein. The pharmaceutical compositions disclosed herein include a first therapeutic agent that is calcitonin, in free or salt form; a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid; and a pharmaceutically acceptable excipient, carrier or diluent. The methods disclosed herein for treating inflammatory or degenerative diseases in a subject include administering a therapeutically effective amount of calcitonin, in free or salt form, to the subject; and co-administering, as part of a combination therapy, a therapeutically effective amount of a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid to the subject. | 09-04-2014 |
20150125522 | ORAL DELIVERY OF PEPTIDE PHARMACEUTICAL COMPOSITIONS - Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide. | 05-07-2015 |
Patent application number | Description | Published |
20100022506 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 01-28-2010 |
20100173899 | DIPEPTIDE ANALOGS AS COAGULATION FACTOR INHIBITORS - Disclosed are novel dipeptide analogs compounds of Formula (I), (II) or (III): | 07-08-2010 |
20110028446 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 02-03-2011 |
20110059940 | 2-Aryl Glycinamide Derivatives - The disclosure provides compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their uses in inhibiting β-amyloid peptide (β-AP) production. | 03-10-2011 |
20120270853 | ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (I): | 10-25-2012 |
20140038969 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (VIII): | 02-06-2014 |
20140163002 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (Ia): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same. | 06-12-2014 |
20140221338 | NOVEL MACROCYCLES AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (Ia): or a stereoisomer, a tautomer, or a pharmaceutically acceptable salt thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same. | 08-07-2014 |
20150057262 | CYCLIC P1 LINKERS AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (Ia): | 02-26-2015 |
20150203492 | DIHYDROPYRIDONE P1 AS FACTOR XIA INHIBITORS - The present invention provides compounds of Formula (X): (Formula (X), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same. | 07-23-2015 |
Patent application number | Description | Published |
20120264207 | POLYMERIC MEMBERS AND METHODS FOR MARKING POLYMERIC MEMBERS - Generally, polymeric members and laser marking methods for producing visible marks on polymeric members, such as on thin and/or curved surfaces. The laser marking methods can include methods of laser marking straws with the step of matching laser source properties to the properties of straws being marked or with the step of laser marking straws having photochromic dyes. | 10-18-2012 |
20130007903 | EFFICIENT HAPLOID CELL SORTING FLOW CYTOMETER SYSTEMS - A flow cytometer system for sorting haploid cells, specifically sperm cells, may include an intermittingly punctuated radiation emitter, such as a pulsed laser. Embodiments include a beam manipulator and even split radiation beams directed to multiple nozzles. Differentiation of sperm characteristics with increased resolution may efficiently allow differentiated sperm cells to be separated at higher speeds and even into subpopulations having higher purity. | 01-03-2013 |
20140023813 | POLYMERIC MEMBERS AND METHODS FOR MARKING POLYMERIC MEMBERS - Generally, polymeric members and laser marking methods for producing visible marks on polymeric members, such as on thin and/or curved surfaces. The laser marking methods can include methods of laser marking straws with the step of matching laser source properties to the properties of straws being marked or with the step of laser marking straws having photochromic dyes. | 01-23-2014 |
20140046126 | TWO-DIMENSIONAL BAR CODES IN ASSISTED REPRODUCTIVE TECHNOLOGIES - A container suitable for storing biological material which is laser etched with a two-dimensional bar code and methods for producing the same. The container can be in the form of a straw having a thickness between about 0.1 mm and about 0.3 mm or can be in the form of another container that holds multiple straws. The laser etched mark can be in the form of a two-dimensional bar code may be located on an exterior surface of the container, and when the container is a straw, it remains unwarped and impermeable to fluids. | 02-13-2014 |
20140051111 | METHOD FOR CONTINUOUSLY REGULATING FLUID PRESSURE - A method of continuously regulating fluid pressure of a first fluid in a fluid flow path by continuously adjusting at least one fluid flow characteristic of a second fluid flow which is engaged with the first fluid flow through a flexible barrier. | 02-20-2014 |